{"protocolSection": {"identificationModule": {"nctId": "NCT00797862", "orgStudyIdInfo": {"id": "CSPA100A2307"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension", "officialTitle": "A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension", "acronym": "ACCELERATE"}, "statusModule": {"statusVerifiedDate": "2011-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-11"}, "primaryCompletionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-24", "studyFirstSubmitQcDate": "2008-11-24", "studyFirstPostDateStruct": {"date": "2008-11-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-21", "resultsFirstSubmitQcDate": "2011-04-21", "resultsFirstPostDateStruct": {"date": "2011-05-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-10-07", "lastUpdatePostDateStruct": {"date": "2011-10-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.", "detailedDescription": "This study was designed to evaluate if patients with hypertension treated early with a combination therapy would achieve better blood pressure (BP) control, than patients being treated with a classical sequential add-on therapy.\n\nThe study compared the effects of the two treatment strategies: Treatment initiation on a single compound, either with aliskiren or amlodipine, and then continuation with the combination of both versus treatment initiation with the combination of aliskiren/amlodipine and then continuation with the combination. The study also evaluated if the overall mean sitting systolic blood pressure (msSBP)-lowering effect during the study, as well as the change from baseline to study end in msSBP, are superior in the group having received combination therapy from the beginning.\n\nThe study further evaluated the BP-lowering efficacy and tolerability of both treatment strategies."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Aliskiren", "Amlodipine", "Hypertension", "SPA1000", "Norvasc"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1254, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren + Amlodipine", "type": "EXPERIMENTAL", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "interventionNames": ["Drug: Amlodipine", "Drug: hydrochlorothiazide", "Drug: Aliskiren"]}, {"label": "Aliskiren Start - Amlodipine Add-On", "type": "EXPERIMENTAL", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "interventionNames": ["Drug: Amlodipine", "Drug: hydrochlorothiazide", "Drug: Aliskiren"]}, {"label": "Amlodipine Start- Aliskiren Add-On", "type": "EXPERIMENTAL", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "interventionNames": ["Drug: Amlodipine", "Drug: hydrochlorothiazide", "Drug: Aliskiren"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.", "armGroupLabels": ["Aliskiren + Amlodipine", "Aliskiren Start - Amlodipine Add-On", "Amlodipine Start- Aliskiren Add-On"], "otherNames": ["Norvasc"]}, {"type": "DRUG", "name": "hydrochlorothiazide", "description": "Hydrochlorothiazide 12.5 mg capsules were taken orally once daily", "armGroupLabels": ["Aliskiren + Amlodipine", "Aliskiren Start - Amlodipine Add-On", "Amlodipine Start- Aliskiren Add-On"], "otherNames": ["Esidrix", "HydroDIURIL", "Oretic", "Ezide", "Hydro-Par"]}, {"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.", "armGroupLabels": ["Aliskiren + Amlodipine", "Aliskiren Start - Amlodipine Add-On", "Amlodipine Start- Aliskiren Add-On"], "otherNames": ["SPA 100"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks", "description": "Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate.", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks"}, {"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24", "description": "Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate.", "timeFrame": "Baseline to 24 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 32", "description": "Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate.", "timeFrame": "Baseline to 32 weeks"}, {"measure": "Overall Mean Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Over 8, 16, and 24 Weeks", "description": "Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate.", "timeFrame": "Baseline, 8 weeks, 16 weeks and 24 weeks"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 24", "description": "Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate.", "timeFrame": "Baseline to 24 weeks"}, {"measure": "Percentage of Participants Achieving Overall Blood Pressure Control at 8, 16, 24 and 32 Weeks Endpoints", "description": "Systolic \\& Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP \\<140 mmHg and msDBP \\<90 mmHg) at weeks 8, 16, 24 \\& 32 endpoints.", "timeFrame": "Baseline to week 8, 16, 24 and 32 endpoints"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients \u2265 18 years of age\n* Participants with essential hypertension:\n\n  * Naive participants must have a mean sitting Systolic Blood Pressure (msSBP) \u2265 150 mmHg and \\< 180 mmHg at Visit 1 and Visit 2. (Participants are considered 'na\u00efve' if they have never been treated with any antihypertensive medication.)\n  * All participants must have a msSBP \u2265 150 mmHg and \\< 180 mmHg at Visit 2\n* Written informed consent to participate in this study prior to any study procedures\n\nExclusion Criteria:\n\n* Severe hypertension\n* Pregnant or nursing (lactating) women\n* Pre-menopausal women not taking accepted form of birth control\n* Serum potassium \u2265 5.5 mEq/L (mmol/L) at Visit 1\n* History of cardiovascular conditions\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Investigative Site", "city": "Toronto", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigative Site", "city": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.93333, "lon": -84.08333}}, {"facility": "Investigative Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Investigative Site", "city": "Bonn", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Investigative Site", "city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Investigative Site", "city": "Guatemala city", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Investigative Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigative Site", "city": "Basel", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}, {"facility": "Investigative Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Investigative Site", "city": "Caracas", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}]}, "referencesModule": {"references": [{"pmid": "26489809", "type": "DERIVED", "citation": "Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18."}, {"pmid": "21236483", "type": "DERIVED", "citation": "Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub 2011 Jan 12."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A 2-4 week single-blind placebo run in. 7 patients were assigned a randomization number in error (3 each in the aliskiren/amlodipine initial treatment and aliskiren based add-on regimens and 1 in the amlodipine based add-on regimen). These patients did not take any double-blind study medication and were excluded from the Full Analysis Set (FAS).", "groups": [{"id": "FG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "FG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "FG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "3 participants were mis-randomized and discontinued. Only 617 participants received study drug.", "numSubjects": "620"}, {"groupId": "FG001", "comment": "3 participants were mis-randomized and discontinued. Only 315 participants received study drug.", "numSubjects": "318"}, {"groupId": "FG002", "comment": "1 participant was mis-randomized and discontinued. Only 315 participants received study drug.", "numSubjects": "316"}]}, {"type": "Entered Double-Blind Treatment (FAS)", "achievements": [{"groupId": "FG000", "numSubjects": "617"}, {"groupId": "FG001", "numSubjects": "315"}, {"groupId": "FG002", "numSubjects": "315"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "496"}, {"groupId": "FG001", "numSubjects": "250"}, {"groupId": "FG002", "numSubjects": "230"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "124"}, {"groupId": "FG001", "numSubjects": "68"}, {"groupId": "FG002", "numSubjects": "86"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "44"}, {"groupId": "FG002", "numSubjects": "58"}]}, {"type": "Abnormal Test Procedure Result", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "No longer required study medication", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Administrative Problem", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Mis-randomized", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "BG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "BG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "620"}, {"groupId": "BG001", "value": "318"}, {"groupId": "BG002", "value": "316"}, {"groupId": "BG003", "value": "1254"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.1", "spread": "10.81"}, {"groupId": "BG001", "value": "58.4", "spread": "10.83"}, {"groupId": "BG002", "value": "58.1", "spread": "10.93"}, {"groupId": "BG003", "value": "58.1", "spread": "10.84"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "305"}, {"groupId": "BG001", "value": "154"}, {"groupId": "BG002", "value": "160"}, {"groupId": "BG003", "value": "619"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "315"}, {"groupId": "BG001", "value": "164"}, {"groupId": "BG002", "value": "156"}, {"groupId": "BG003", "value": "635"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks", "description": "Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 8 weeks, 16 weeks, and 24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25.34", "spread": "0.436"}, {"groupId": "OG001", "value": "-17.94", "spread": "0.600"}, {"groupId": "OG002", "value": "-19.81", "spread": "0.611"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24", "description": "Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-27.37", "spread": "0.546"}, {"groupId": "OG001", "value": "-26.34", "spread": "0.738"}, {"groupId": "OG002", "value": "-25.52", "spread": "0.782"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 32", "description": "Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to 32 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.96", "spread": "0.323"}, {"groupId": "OG001", "value": "-12.96", "spread": "0.446"}, {"groupId": "OG002", "value": "-11.62", "spread": "0.467"}]}]}]}, {"type": "SECONDARY", "title": "Overall Mean Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Over 8, 16, and 24 Weeks", "description": "Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 8 weeks, 16 weeks and 24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.39", "spread": "0.247"}, {"groupId": "OG001", "value": "-8.37", "spread": "0.340"}, {"groupId": "OG002", "value": "-9.02", "spread": "0.347"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 24", "description": "Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.64", "spread": "0.319"}, {"groupId": "OG001", "value": "-13.22", "spread": "0.431"}, {"groupId": "OG002", "value": "-12.25", "spread": "0.457"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Overall Blood Pressure Control at 8, 16, 24 and 32 Weeks Endpoints", "description": "Systolic \\& Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP \\<140 mmHg and msDBP \\<90 mmHg) at weeks 8, 16, 24 \\& 32 endpoints.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure. Last post-baseline observation was carried forward to each visit for the analysis of blood pressure control.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Baseline to week 8, 16, 24 and 32 endpoints", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"title": "Week 8 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.5", "spread": "0.566"}, {"groupId": "OG001", "value": "22.8", "spread": "0.781"}, {"groupId": "OG002", "value": "25.2", "spread": "0.816"}]}]}, {"title": "Week 16 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.9"}, {"groupId": "OG001", "value": "33.3"}, {"groupId": "OG002", "value": "40.9"}]}]}, {"title": "Week 24 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.4"}, {"groupId": "OG001", "value": "62.8"}, {"groupId": "OG002", "value": "57.8"}]}]}, {"title": "Week 32 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.6"}, {"groupId": "OG001", "value": "59.0"}, {"groupId": "OG002", "value": "53.4"}]}]}]}, {"type": "POST_HOC", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 32", "description": "Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 \\& 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msSBP was a covariate.", "populationDescription": "The analysis population included participants in the Full Analysis Set, (randomized participants who received at least one dose of study drug) for whom efficacy data was available for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to 32 weeks", "groups": [{"id": "OG000", "title": "Aliskiren+Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG001", "title": "Aliskiren Start-Amlodipine Add On", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks."}, {"id": "OG002", "title": "Amlodipine Start-Aliskiren Add On", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "604"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.42", "spread": "0.566"}, {"groupId": "OG001", "value": "-25.75", "spread": "0.781"}, {"groupId": "OG002", "value": "-24.32", "spread": "0.816"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren + Amlodipine", "description": "Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "seriousNumAffected": 14, "seriousNumAtRisk": 617, "otherNumAffected": 196, "otherNumAtRisk": 617}, {"id": "EG001", "title": "Aliskiren", "description": "Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "seriousNumAffected": 9, "seriousNumAtRisk": 315, "otherNumAffected": 81, "otherNumAtRisk": 315}, {"id": "EG002", "title": "Amlodipine", "description": "Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.", "seriousNumAffected": 9, "seriousNumAtRisk": 315, "otherNumAffected": 104, "otherNumAtRisk": 315}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Hypertensive heart disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Gastric haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Parotid gland enlargement", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Sigmoiditis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Stress urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 315}]}, {"term": "Urinary bladder polyp", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Varicocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 315}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 131, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 53, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 76, "numAtRisk": 315}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 315}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 31, "numAtRisk": 617}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 315}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 315}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with it's investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862- 778- 8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}